A Phase 2 interventional study of ABT-SLV187 and Oral Levodopa/Carbidopa in Advanced Parkinson's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 30 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-04-21.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To explore the safety, tolerability, pharmacokinetics and efficacy of ABT-SLV187 in advanced Parkinson's disease (PD) patients with severe motor complications. The complications of medical devices for the naso-jejunum (NJ) infusion system of ABT-SLV187 will also be investigated.
179 studies on the registry are indexed under Dyskinesias; 24 are open to participants now.
This study's enrollment of 8 is below the median of 36 across 139 interventional studies indexed under Dyskinesias.
Browse Dyskinesias studies →AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following a 28-day Run-in Period where participants are switched from prior anti-PD medications to monotherapy with an oral 100 mg levodopa/10 mg carbidopa tablet (optimized every 3rd hour during waking hours), participants receive ABT-SLV187 (levodopa-carbidopa intestinal gel), administered over 16 hours a day with an infusion pump directly into the proximal jejunum by an NJ tube, for 3 weeks. The individually-adjusted infusion dose (composed of the morning dose, the continuous maintenance dose, and the extra dose) is optimized by the Investigator for each participant during the study based on the participant's symptoms.
Drug: ABT-SLV187 · Drug: Oral Levodopa/Carbidopa · Device: Infusion Pump: CADD-Legacy® 1400 Pump · Device: NJ-Tube: Silicon ED Tube · Device: Adaptor: Hakko Adaptor
Also known as: DUOPA™ (carbidopa and levodopa Enteral Suspension), DUODOPA®, Levodopa-carbidopa intestinal gel (LCIG)
Drug pages: Levodopa · Carbidopa
Tablet; contains 100 mg levodopa and 10 mg carbidopa
General infusion pump, manufactured by Smiths Medical (US)
Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation During the Run-in Period
AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. SAE: an event that results in the death of a subject, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, or other important medical event. Severity was rated as mild, moderate, or severe. AEs of special interest included: device-associated gastrointestinal disorders; cardiovascular fatalities; aspiration including aspiration pneumonia; a diagnosis of peripheral polyneuropathy (axonal, demyelinating or mixed type); possible symptoms of peripheral polyneuropathy; clinically significant weight loss. 'AEs at least possibly related' are defined as those that were assessed by investigator as probably related or possibly related.
Time frame: During the Run-in period (up to approximately 28 days)
Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation During the ABT-SLV187 Treatment Period
AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. SAE: an event that results in the death of a subject, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, or other important medical event. Severity was rated as mild, moderate, or severe. AEs of special interest included: device-associated gastrointestinal disorders; cardiovascular fatalities; aspiration including aspiration pneumonia; a diagnosis of peripheral polyneuropathy (axonal, demyelinating or mixed type); possible symptoms of peripheral polyneuropathy; clinically significant weight loss. 'AEs at least possibly related' are defined as those that were assessed by investigator as probably related or possibly related.
Time frame: From NJ placement to end of ABT-SLV187 Treatment Period (Day 21) +30 days
Number of Participants With Potentially Clinically Significant (PCS) Hematology Results During the ABT-SLV187 Treatment Period
M=male, F=female, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration.
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Number of Participants With PCS Blood Biochemistry Results During the ABT-SLV187 Treatment Period
M=male, F=female, γ-GTP=gamma-glutamyl transpeptidase.
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Number of Participants With PCS Values in Special Laboratory Parameters During the ABT-SLV187 Treatment Period
M=male, F=female
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Number of Participants With Potentially Clinically Significant Urinalysis Results During the ABT-SLV187 Treatment Period
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Number of Participants With Potentially Clinically Significant (PCS) Vital Signs Results During the ABT-SLV187 Treatment Period
↓=decrease, ↑=increase, BL=baseline, temp.=temperature, SBP=systolic blood pressure, Sup.=supine, Sta.=standing, DBP=diastolic blood pressure.
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Results During the ABT-SLV187 Treatment Period
High potentially clinically significant Bazett's heart rate-corrected QT interval (QTcB) values were: 450 msec for males / 470 msec for females.
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the "Normal" State on the Treatment Response Scale (TRS) I
Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks: rest, finger taps, rapid alternating movement of hands, arising from chair and gait, including confirmation of postural stability. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the following Video Assessment and Treatment Response Scale (TRS) under blinded conditions: Finger Taps, Rapid Alternating Movement of Hands, Arising from Chair, Gait, Body Bradykinesia and Hypokinesia, Dyskinesia. The average of the neurologists' evaluations was calculated as a percentage of ratings in the "Normal" state (ie, "mild OFF" to "ON with mild dyskinesia") on the TRS I (total 10 assessments per day).
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the "OFF" and "Dyskinesia" States on the TRS I and the "Normal," "OFF," and "Dyskinesia" States on the TRS II
Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks: rest, finger taps, rapid alternating movement of hands, arising from chair and gait, including confirmation of postural stability. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the following Video Assessment and TRS under blinded conditions: Finger Taps, Rapid Alternating Movement of Hands, Arising from Chair, Gait, Body Bradykinesia and Hypokinesia, Dyskinesia for TRS I, with the addition of Tremor at Rest and Postural Stability for TRS II. The average of the 3 neurologists' evaluations was calculated as a percentage of ratings in the "Normal" state (ie, "mild OFF" to "ON with mild dyskinesia"), the "Off" state ("moderate OFF" to "severe OFF"), and the "Dyskinesia" state ("ON with moderate dyskinesia" to "ON with severe dyskinesia") on the TRS I or II.
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Change From Baseline to the End of Treatment in Parkinson's Disease Diary Assessment
For each half hour period during 3 consecutive days prior to each assessment of the diary, participants (and/or their caregivers) entered into a diary whether they were asleep, in the ON motor state or in the OFF motor state in the following 5 grades: asleep, OFF, ON (no dyskinesia \[D\]), ON with non-troublesome dyskinesia (NTD), ON with troublesome dyskinesia (TD). ON time is when PD symptoms are well controlled by the drug. OFF time is when PD symptoms are not adequately controlled by the drug. Dyskinetic time is time with involuntary muscle movement. The ON or OFF times were calculated as the average of 3 daily times from the diaries. w/o = without, w/ = with
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Baseline and Endpoint (End of Treatment) Video Scoring of Unified Parkinson's Disease Rating Scale (UPDRS) Items and Dyskinesia
Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the video under blinded conditions using the following assessments: Tremor at Rest (UPDRS item #20), Finger Taps (UPDRS #23), Rapid Alternating Movement of Hands (UPDRS #25), Arising from Chair (UPDRS #27), Gait (UPDRS #29), Postural Stability (UPDRS #30), Body Bradykinesia and Hypokinesia (UPDRS #31), and Dyskinesia (evaluated with the Goetz Dyskinesia Rating Scale). The UPDRS score is the sum of the answers to individual questions, each of which are measured on a 5-point scale (0-4), with higher scores associated with more disability. The Goetz Dyskinesia Rating Scale is a 5-point scale of the severity of dyskinesias, from 0 (absent) to 4 (violent dyskinesias).
Time frame: Baseline (Day -1), Endpoint (Day 21)
Mean Change From Baseline to the End of Treatment in UPDRS Total Scores and Subscores
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score ranges from 0-176, with 176 representing the worst (total) disability, and 0 no disability. The Part I Score is the sum of the answers to the 4 questions related to Mentation, Behavior and Mood, and ranges from 0-16. The Part II score is the sum of the answers to the 13 questions related to Activities of Daily Living, and ranges from 0-52. The Part III score is the sum of the 27 answers related to Motor Examination, and ranges from 0-108. The Part IV Score is the sum of the answers to the 11 questions related to Complications of Therapy, and ranges from 0-23. The Part IV dyskinesia subscore ranges from 0-12. For each part of the UPDRS, higher scores are associated with more disability.
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Change From Baseline to the End of Treatment in the Japanese Version of Parkinson's Disease Questionnaire 39 (PDQ-39) Total Score and Domain Scores
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients, including Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort, as well as a Summary Index Total Score. Scores for each are on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Modified Hoehn and Yahr Staging at Baseline and End of Treatment
Participant's ON and OFF states staged according to the Modified Hoehn and Yahr criteria, an 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. ON time is when PD symptoms are well controlled by the drug. OFF time is when PD symptoms are not adequately controlled by the drug.
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Schwab and England Activities of Daily Living Scale at Baseline and End of Treatment
The Schwab and England scale was used to rate the subject's activities of daily living by recording the percentage score, ranging between being completely independent (100%) and totally dependent (10%).
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Clinical Global Impression - Severity (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Baseline and End of Treatment
The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, and among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Time to Reach Peak Plasma Concentration (Tmax) After Administration of Oral Levodopa/Carbidopa (L/C) Tablets and Intra-jejunal Administration of ABT-SLV187
Tmax of levodopa, carbidopa, and its metabolite 3-O-methyldopa (3-OMD) after administration of oral L/C tablets and intra-jejunal administration of ABT-SLV187.
Time frame: Baseline (Day -1): pre-dose; 15, 30, 45, 60 mins post-morning dose; every 30 mins thereafter for 12 hrs. Day 21: pre-dose; 15, 30, 45, 60 mins post-infusion; every 30 mins from hrs 1 to 12 post-infusion; every 2 hrs from 12 to 16 hrs post-infusion.
Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), Trough Plasma Concentration (Cmin), and Cmin Within 2 and 12 Hours (Cmin [2-12 Hours]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
Cmax, Cavg, Cmin, and Cmin (2-12 hours) of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). Cmin values for levodopa and carbidopa during the 16 hours of infusion were observed either at time 0 or 15 min after start of the infusion and were a result of drug washout prior to establishment of infusion.
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
The Area Under the Concentrations-time Curve From 0 to 12 and 0 to 16 Hours (AUC0-12, AUC0-16) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
AUC0-12 and AUC0-16 of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
AUC0-12/Dose0-12, AUC0-16/Dose0-16 After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
AUC0-12/Dose0-12 of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). AUC0-16/Dose0-16 of levodopa, carbidopa, and 3-OMD after administration of intra-jejunal administration of ABT-SLV187 (Day 21).
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Degree of Fluctuation (2-12 Hours) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
Degree of Fluctuation (calculated as \[Cmax - Cmin\] / Cavg)) of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Ratio of Metabolite 3-OMD to Levodopa (M/P [AUC0-12]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
M/P (AUC0-12) after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
Number of Participants With Product Quality Complaints (PQC) During the ABT-SLV187 Treatment Period
Time frame: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)
| Milestone | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Started | 8 |
| Started lcig | 6 |
| Completed | 5 |
| Not completed | 3 |
AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. SAE: an event that results in the death of a subject, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, or other important medical event. Severity was rated as mild, moderate, or severe. AEs of special interest included: device-associated gastrointestinal disorders; cardiovascular fatalities; aspiration including aspiration pneumonia; a diagnosis of peripheral polyneuropathy (axonal, demyelinating or mixed type); possible symptoms of peripheral polyneuropathy; clinically significant weight loss. 'AEs at least possibly related' are defined as those that were assessed by investigator as probably related or possibly related.
| participants | Oral Levodopa/Carbidopa Tablet |
|---|---|
| AE | 7 |
| AE at least possibly related to study drug/device | 5 |
| Severe AE | 0 |
| SAE | 0 |
| AE leading to discontinuation of study drug | 1 |
| SAE at least possibly drug or drug device-related | 0 |
| AE of special interest | 0 |
| AE caused by study drug | 5 |
| AE caused by devices | NA |
| AE caused by NJ tube insertion | NA |
| Fatal AE | 0 |
AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. SAE: an event that results in the death of a subject, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, or other important medical event. Severity was rated as mild, moderate, or severe. AEs of special interest included: device-associated gastrointestinal disorders; cardiovascular fatalities; aspiration including aspiration pneumonia; a diagnosis of peripheral polyneuropathy (axonal, demyelinating or mixed type); possible symptoms of peripheral polyneuropathy; clinically significant weight loss. 'AEs at least possibly related' are defined as those that were assessed by investigator as probably related or possibly related.
| participants | Levodopa-carbidopa Intestinal Gel |
|---|---|
| AE | 4 |
| AE at least possibly related to study drug/device | 3 |
| Severe AE | 1 |
| SAE | 1 |
| AE leading to discontinuation of study drug | 1 |
| SAE at least possiby drug or drug device-related | 1 |
| AE of special interest | 2 |
| AE caused by study drug | 3 |
| AE caused by devices | 0 |
| AE caused by NJ tube insertion | 1 |
| Fatal AE | 0 |
M=male, F=female, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration.
| participants | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Low PCS Hematocrit [%]: 39.8 M / 33.4 F | 3 |
| High PCS Hematocrit [%]: 51.8 M / 44.9 F | 0 |
| Low PCS Hemoglobin [g/dL]: 13.5 M / 11.3 F | 3 |
| High PCS Hemoglobin [g/dL]: 17.6 M / 15.2 F | 0 |
| Low PCS RBC Count [*10^4/µL]: 427 M / 376 F | 3 |
| High PCS RBC Count [*10^4/µL]: 570 M / 500 F | 0 |
| Low PCS WBC Count [/µL]: 3900 M / 3500 F | 1 |
| High PCS WBC Count [/µL]: 9800 M / 9100 F | 0 |
| Low PCS Neutrophils [%]: 40.0 | 0 |
| High PCS Neutrophils [%]: 74.0 | 0 |
| Low PCS Lymphocytes [%]: 18.0 | 0 |
| High PCS Lymphocytes [%]: 59.0 | 0 |
| Low PCS Monocytes [%]: 0.0 | 0 |
| High PCS Monocytes [%]: 8.0 | 1 |
| Low PCS Basophils [%]: 0.0 | 0 |
| High PCS Basophils [%]: 2.0 | 0 |
| Low PCS Eosinophils [%]: 0.0 | 0 |
| High PCS Eosinophils [%]: 6.0 | 0 |
| Low PCS Platelet count [*10^4/µL]: 13.1 M / 13.0 F | 0 |
| High PCS Platelet count [*10^4/µL]: 36.2 M/ 36.9 F | 1 |
| Low PCS MCV [FL]: 82.7 M / 79.0 F | 0 |
| High PCS MCV [FL]: 101.6 M / 100.0 F | 0 |
| Low PCS MCH [Pg]: 28 M / 26.3 F | 0 |
| High PCS MCH [Pg]: 34.6 M / 34.3 F | 0 |
| Low PCS MCHC [%]: 31.6 M / 30.7 F | 1 |
| High PCS MCHC [%]: 36.6 M / 36.6 F | 0 |
M=male, F=female, γ-GTP=gamma-glutamyl transpeptidase.
| participants | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Low PCS Blood urea nitrogen [mg/dL]: 6 | 0 |
| High PCS Blood urea nitrogen [mg/dL]: 20 | 1 |
| Low Creatinine [mg/dL]: 0.61 M / 0.47 F | 2 |
| High Creatinine [mg/dL]: 1.04 M / 0.79 F | 0 |
| Low PCS Total bilirubin [mg/dL]: 0.2 | 0 |
| High PCS Total bilirubin [mg/dL]: 1.0 | 0 |
| Low PCS Alanine aminotransferase [U/L]: 5 | 0 |
| High PCS Alanine aminotransferase [U/L]: 40 | 0 |
| Low PCS Aspartate aminotransferase [U/L]: 10 | 1 |
| High PCS Aspartate aminotransferase [U/L]: 40 | 0 |
| Low PCS Alkaline phosphatase [U/L]: 115 | 0 |
| High PCS Alkaline phosphatase [U/L]: 359 | 1 |
| Low PCS γ-GTP [U/L]: 0 | 0 |
| High PCS γ-GTP [U/L]: 70 M / 30 F | 0 |
| Low PCS Sodium [mEq/L]: 136 | 1 |
| High PCS Sodium [mEq/L]: 147 | 0 |
| Low PCS Potassium [mEq/L]: 3.6 | 0 |
| High PCS Potassium [mEq/L]: 5.0 | 0 |
| Low PCS Calcium [mg/dL]: 8.7 | 3 |
| High PCS Calcium [mg/dL]: 10.1 | 0 |
| Low PCS Chloride [mEq/L]: 98 | 1 |
| High PCS Chloride [mEq/L]: 109 | 0 |
| Low PCS Magnesium [mg/dL]: 1.8 | 0 |
| High PCS Magnesium [mg/dL]: 2.6 | 1 |
| Low PCS Inorganic Phosphors [mg/dL]: 2.4 | 0 |
| High PCS Inorganic Phosphors [mg/dL]: 4.3 | 1 |
| Low PCS Uric acid [mg/dL]: 3.7 M / 2.5 F | 2 |
| High PCS Uric acid [mg/dL]: 7 M / 7.0 F | 0 |
| Low PCS Total cholesterol [mg/dL]: 150 | 0 |
| High PCS Total cholesterol [mg/dL]: 219 | 2 |
| Low PCS Total protein [g/dL]: 6.7 | 5 |
| High PCS Total protein [g/dL]: 8.3 | 0 |
| Low PCS Albumin [g/dL]: 4.0 | 3 |
| High PCS Albumin [g/dL]: 5.0 | 0 |
| Low PCS Glucose [mg/dL]: 70 | 0 |
| High PCS Glucose [mg/dL]: 109 | 1 |
| Low PCS Triglycerides [mg/dL]: 50 | 1 |
| High PCS Triglycerides [mg/dL]: 149 | 0 |
| Low PCS Creatine kinase [U/L]: 57 M / 32 F | 1 |
| High PCS Creatine kinase [U/L]: 197 M / 180 F | 3 |
| Low PCS Bicarbonate [mEq/L]: 22 | 0 |
| High PCS Bicarbonate [mEq/L]: 29 | 0 |
| Low PCS Lactate dehydrogenase [U/L]: 115 | 0 |
| High PCS Lactate dehydrogenase [U/L]: 245 | 1 |
M=male, F=female
| participants | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Low PCS Vitamin B6 pyridoxamine [ng/mL]: </= 0.6 | 0 |
| Low PCS Vitamin B6 pyridoxal [ng/mL]: 6.0 M/4.0 F | 4 |
| High PCS Vitamin B6 pyridoxal [ng/mL]: 40 M / 19 F | 1 |
| Low PCS Vitamin B6 pyridoxine [ng/mL]: </= 3.0 | 0 |
| Low PCS Vitamin B12 [pg/mL]: 180 | 1 |
| High PCS Vitamin B12 [pg/mL]: 914 | 0 |
| Low PCS Homocysteine [nmol/mL]: 3.7 | 0 |
| High PCS Homocysteine [nmol/mL]: 13.5 | 4 |
| Low PCS Folic acid [ng/mL]: < 3.1 | 1 |
Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks: rest, finger taps, rapid alternating movement of hands, arising from chair and gait, including confirmation of postural stability. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the following Video Assessment and TRS under blinded conditions: Finger Taps, Rapid Alternating Movement of Hands, Arising from Chair, Gait, Body Bradykinesia and Hypokinesia, Dyskinesia for TRS I, with the addition of Tremor at Rest and Postural Stability for TRS II. The average of the 3 neurologists' evaluations was calculated as a percentage of ratings in the "Normal" state (ie, "mild OFF" to "ON with mild dyskinesia"), the "Off" state ("moderate OFF" to "severe OFF"), and the "Dyskinesia" state ("ON with moderate dyskinesia" to "ON with severe dyskinesia") on the TRS I or II.
| percentage of ratings | Levodopa-carbidopa Intestinal Gel |
|---|---|
| TRS I "OFF" state | -15.33 ± 13.04 |
| TRS I "Dyskinesia" state | 0.00 ± 4.71 |
| TRS II "Normal" state | 14.67 ± 18.65 |
| TRS II "OFF" state | -15.33 ± 18.65 |
| TRS II "Dyskinesia" state | 0.67 ± 1.49 |
For each half hour period during 3 consecutive days prior to each assessment of the diary, participants (and/or their caregivers) entered into a diary whether they were asleep, in the ON motor state or in the OFF motor state in the following 5 grades: asleep, OFF, ON (no dyskinesia \[D\]), ON with non-troublesome dyskinesia (NTD), ON with troublesome dyskinesia (TD). ON time is when PD symptoms are well controlled by the drug. OFF time is when PD symptoms are not adequately controlled by the drug. Dyskinetic time is time with involuntary muscle movement. The ON or OFF times were calculated as the average of 3 daily times from the diaries. w/o = without, w/ = with
| hours | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Daily OFF time | -1.02 ± 3.73 |
| Daily ON time w/o D + time w/ NTD | 0.76 ± 3.61 |
| Daily ON time w/o D + time w/ NTD + time w/ TD | 1.02 ± 3.73 |
Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the video under blinded conditions using the following assessments: Tremor at Rest (UPDRS item #20), Finger Taps (UPDRS #23), Rapid Alternating Movement of Hands (UPDRS #25), Arising from Chair (UPDRS #27), Gait (UPDRS #29), Postural Stability (UPDRS #30), Body Bradykinesia and Hypokinesia (UPDRS #31), and Dyskinesia (evaluated with the Goetz Dyskinesia Rating Scale). The UPDRS score is the sum of the answers to individual questions, each of which are measured on a 5-point scale (0-4), with higher scores associated with more disability. The Goetz Dyskinesia Rating Scale is a 5-point scale of the severity of dyskinesias, from 0 (absent) to 4 (violent dyskinesias).
| units on a scale | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Tremor at rest, Baseline | 0.00 ± 0.00 |
| Tremor at rest, Endpoint | 0.00 ± 0.00 |
| Finger taps, Baseline | 0.40 ± 0.55 |
| Finger taps, Endpoint | 0.40 ± 0.55 |
| Rapid alternating movement of hands, Baseline | 1.00 ± 0.00 |
| Rapid alternating movement of hands, Endpoint | 0.60 ± 0.55 |
| Arising from chair, Baseline | 0.10 ± 0.22 |
| Arising from chair, Endpoint | 0.00 ± 0.00 |
| Gait, Baseline | 0.60 ± 0.55 |
| Gait, Endpoint | 0.60 ± 0.55 |
| Postural stability, Baseline | 1.60 ± 0.55 |
| Postural stability, Endpoint | 1.10 ± 0.89 |
| Body bradykinesia and hypokinesia, Baseline | 1.00 ± 0.00 |
| Body bradykinesia and hypokinesia, Endpoint | 0.80 ± 0.27 |
| Dyskinesia, Baseline | 0.40 ± 0.55 |
| Dyskinesia, Baseline | 0.90 ± 0.55 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score ranges from 0-176, with 176 representing the worst (total) disability, and 0 no disability. The Part I Score is the sum of the answers to the 4 questions related to Mentation, Behavior and Mood, and ranges from 0-16. The Part II score is the sum of the answers to the 13 questions related to Activities of Daily Living, and ranges from 0-52. The Part III score is the sum of the 27 answers related to Motor Examination, and ranges from 0-108. The Part IV Score is the sum of the answers to the 11 questions related to Complications of Therapy, and ranges from 0-23. The Part IV dyskinesia subscore ranges from 0-12. For each part of the UPDRS, higher scores are associated with more disability.
| units on a scale | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Total score | -0.60 ± 7.70 |
| Part I | 0.20 ± 0.45 |
| Part II | 0.60 ± 4.93 |
| Part II (Off-time) | -2.20 ± 6.54 |
| Part III | -1.40 ± 4.56 |
| Part IV subscore of dyskinesia | 2.20 ± 2.39 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients, including Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort, as well as a Summary Index Total Score. Scores for each are on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Total score | 1.26 ± 5.48 |
| Domain: Mobility | 10.00 ± 20.16 |
| Domain: Activities of daily living | -0.83 ± 14.25 |
| Domain: Emotional well-being | -8.33 ± 12.84 |
| Domain: Stigma | 1.25 ± 10.27 |
| Domain: Social support | -5.00 ± 6.85 |
| Domain: Cognition | -5.00 ± 13.55 |
| Domain: Communication | 1.67 ± 20.75 |
| Domain: Bodily discomfort | 8.33 ± 30.62 |
Participant's ON and OFF states staged according to the Modified Hoehn and Yahr criteria, an 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. ON time is when PD symptoms are well controlled by the drug. OFF time is when PD symptoms are not adequately controlled by the drug.
| units on a scale | Levodopa-carbidopa Intestinal Gel |
|---|---|
| ON state staging, Baseline | 2.5 (2.5 to 3) |
| ON state staging, Endpoint | 3.0 (2 to 3) |
| OFF state staging, Baseline | 4.0 (4 to 4) |
| OFF state staging, Endpoint | 4.0 (2 to 4) |
The Schwab and England scale was used to rate the subject's activities of daily living by recording the percentage score, ranging between being completely independent (100%) and totally dependent (10%).
| units on a scale | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Baseline | 80.0 (50 to 80) |
| Endpoint | 80.0 (70 to 90) |
The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, and among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.
| participants | Levodopa-carbidopa Intestinal Gel |
|---|---|
| CGI-S, Baseline: Normal | 0 |
| CGI-S, Baseline: Borderline ill | 0 |
| CGI-S, Baseline: Mildly ill | 0 |
| CGI-S, Baseline: Moderately ill | 2 |
| CGI-S, Baseline: Markedly ill | 3 |
| CGI-S, Baseline: Severely ill | 0 |
| CGI-S, Baseline: Among the most extremely ill | 0 |
| CGI-S, Endpoint: Normal | 1 |
| CGI-S, Endpoint: Borderline ill | 0 |
| CGI-S, Endpoint: Mildly ill | 0 |
| CGI-S, Endpoint: Moderately ill | 3 |
| CGI-S, Endpoint: Markedly ill | 1 |
| CGI-S, Endpoint: Severely ill | 0 |
| CGI-S, Endpoint: Among the most extremely ill | 0 |
| CGI-I: Very much improved | 1 |
| CGI-I: Much improved | 3 |
| CGI-I: Minimally improved | 1 |
| CGI-I: No change | 0 |
| CGI-I: Minimally worse | 0 |
| CGI-I: Much worse | 0 |
| CGI-I: Very much worse | 0 |
| participants | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Low PCS Specific gravity: 1.002 | 0 |
| High PCS Specific gravity: 1.030 | 0 |
| Low PCS pH: 4.5 | 0 |
| High PCS pH: 8.0 | 1 |
| High PCS Protein: > trace | 0 |
| High PCS Glucose: > trace | 0 |
| High PCS Occult blood: > negative | 0 |
| High PCS Ketone: > negative | 0 |
↓=decrease, ↑=increase, BL=baseline, temp.=temperature, SBP=systolic blood pressure, Sup.=supine, Sta.=standing, DBP=diastolic blood pressure.
| participants | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Low PCS Weight [kg]: ≥7% ↓ from BL | 0 |
| High PCS Weight [kg]: ≥7% ↑ from BL | 0 |
| High PCS Body temp. [⁰C]: ≥38.8 and ≥1.1 ↑ from BL | 0 |
| Low PCS SBP Sup. [mmHg]: ≤90 and >30 ↓ from BL | 0 |
| High PCS SBP Sup. [mmHg]: ≥180 and >40 ↑ from BL | 0 |
| Low PCS SBP Sta. [mmHg]: ≤90 and >30 ↓ from BL | 1 |
| High PCS SBP Sta. [mmHg]: ≥180 and >40 ↑ from BL | 0 |
| Low PCS SBP Orthostatic [mmHg]: ↓ of ≥30 in SBP | 1 |
| Low PCS DBP Sup. [mmHg]: ≤50 and >30 ↓ from BL | 0 |
| High PCS DBP Sup. [mmHg]: ≥105 and >30 ↑ from BL | 0 |
| Low PCS DBP Sta. [mmHg]: ≤50 and >30 ↓ from BL | 0 |
| High PCS DBP Sta. [mmHg]: ≥105 and >30 ↑ from BL | 0 |
| Low PCS DBP Orthostatic [mmHg]: ↓ of ≥20 in DBP | 1 |
| Pulse rate [bpm]: ≤50 and >30 ↓ from BL | 0 |
| Pulse rate [bpm]: ≥120 and >30 ↑ from BL | 0 |
High potentially clinically significant Bazett's heart rate-corrected QT interval (QTcB) values were: 450 msec for males / 470 msec for females.
| participants | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Results During the ABT-SLV187 Treatment Period | 0 |
Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks: rest, finger taps, rapid alternating movement of hands, arising from chair and gait, including confirmation of postural stability. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the following Video Assessment and Treatment Response Scale (TRS) under blinded conditions: Finger Taps, Rapid Alternating Movement of Hands, Arising from Chair, Gait, Body Bradykinesia and Hypokinesia, Dyskinesia. The average of the neurologists' evaluations was calculated as a percentage of ratings in the "Normal" state (ie, "mild OFF" to "ON with mild dyskinesia") on the TRS I (total 10 assessments per day).
| percentage of ratings | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the "Normal" State on the Treatment Response Scale (TRS) I | 15.33 ± 14.26 |
Tmax of levodopa, carbidopa, and its metabolite 3-O-methyldopa (3-OMD) after administration of oral L/C tablets and intra-jejunal administration of ABT-SLV187.
| hours | Oral Levodopa-carbidopa Tablets | Levodopa-carbidopa Intestinal Gel |
|---|---|---|
| Levodopa | 3.0 ± 3.5 | 1.0 ± 0.50 |
| Carbidopa | 7.8 ± 2.8 | 4.5 ± 4.2 |
| 3-OMD | 11 ± 0.76 | 11 ± 0.79 |
Cmax, Cavg, Cmin, and Cmin (2-12 hours) of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). Cmin values for levodopa and carbidopa during the 16 hours of infusion were observed either at time 0 or 15 min after start of the infusion and were a result of drug washout prior to establishment of infusion.
| µg/mL | Oral Levodopa-carbidopa Tablets | Levodopa-carbidopa Intestinal Gel |
|---|---|---|
| Cmax: Levodopa | 5.96 ± 0.77 | 4.38 ± 1.15 |
| Cmax: Carbidopa | 0.128 ± 0.03 | 0.273 ± 0.07 |
| Cmax: 3-OMD | 9.27 ± 2.17 | 11.7 ± 1.25 |
| Cavg: Levodopa | 2.37 ± 0.26 | 2.87 ± 0.66 |
| Cavg: Carbidopa | 0.079 ± 0.02 | 0.172 ± 0.04 |
| Cavg: 3-OMD | 7.36 ± 1.93 | 9.80 ± 1.23 |
| Cmin: Levodopa | 0.268 ± 0.43 | 0.061 ± 0.03 |
| Cmin: Carbidopa | 0.014 ± 0.02 | 0.016 ± 0.01 |
| Cmin: 3-OMD | 5.67 ± 1.60 | 7.78 ± 0.63 |
| Cmin (2-12 hours): Levodopa | 0.734 ± 0.43 | 2.38 ± 0.77 |
| Cmin (2-12 hours):Carbidopa | 0.050 ± 0.02 | 0.130 ± 0.04 |
| Cmin (2-12 hours): 3-OMD | 5.72 ± 1.53 | 8.14 ± 0.94 |
AUC0-12 and AUC0-16 of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).
| µg*h/mL | Oral Levodopa-carbidopa Tablets | Levodopa-carbidopa Intestinal Gel |
|---|---|---|
| AUC0-12: Levodopa | 28.4 ± 3.08 | 34.4 ± 7.95 |
| AUC0-12: Carbidopa | 0.94 ± 0.18 | 2.07 ± 0.52 |
| AUC0-12: 3-OMD | 88.3 ± 23.1 | 118 ± 14.7 |
| AUC0-16: Levodopa | NA ± NA | 46.7 ± 10.7 |
| AUC0-16: Carbidopa | NA ± NA | 2.80 ± 0.666 |
| AUC0-16: 3-OMD | NA ± NA | 165 ± 21.2 |
AUC0-12/Dose0-12 of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). AUC0-16/Dose0-16 of levodopa, carbidopa, and 3-OMD after administration of intra-jejunal administration of ABT-SLV187 (Day 21).
| µg*h/mL/mg | Oral Levodopa-carbidopa Tablets | Levodopa-carbidopa Intestinal Gel |
|---|---|---|
| AUC0-12/Dose0-12: Levodopa | 0.036 ± 0.008 | 0.032 ± 0.006 |
| AUC0-12/Dose0-12: Carbidopa | 0.012 ± 0.003 | 0.008 ± 0.001 |
| AUC0-12/Dose0-12: 3-OMD | 0.112 ± 0.029 | 0.113 ± 0.022 |
| AUC0-16/Dose0-16: Levodopa | NA ± NA | 0.035 ± 0.007 |
| AUC0-16/Dose0-16: Carbidopa | NA ± NA | 0.008 ± 0.001 |
| AUC0-16/Dose0-16: 3-OMD | NA ± NA | 0.125 ± 0.025 |
Degree of Fluctuation (calculated as \[Cmax - Cmin\] / Cavg)) of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).
| ratio | Oral Levodopa-carbidopa Tablets | Levodopa-carbidopa Intestinal Gel |
|---|---|---|
| Levodopa | 2.1 ± 0.59 | 0.38 ± 0.16 |
| Carbidopa | 0.97 ± 0.20 | 0.78 ± 0.25 |
| 3-OMD | 0.48 ± 0.10 | 0.35 ± 0.07 |
M/P (AUC0-12) after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21).
| ratio | Oral Levodopa-carbidopa Tablets | Levodopa-carbidopa Intestinal Gel |
|---|---|---|
| Ratio of Metabolite 3-OMD to Levodopa (M/P [AUC0-12]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187 | 3.11 ± 0.71 | 3.53 ± 0.70 |
| participants | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Any PQC | 2 |
| Any PQC related to an AE | 0 |
| Any serious PQC | 0 |
| Any PQC leading to discontinuation of study drug | 0 |
| Any PQC by pump | 0 |
| Any PQC by NJ-tube insertion | 2 |
| Any PQC by adapter | 0 |
| Any PQC by cassettes | 1 |
| Without any PQCs | 4 |
Collected over AEs: from the time of first study drug administration in the Run-in Period to 30 days following completion or discontinuation of study drug administration (up to 79 days). SAEs from the time of Screening (up to 93 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Levodopa-carbidopa Tablets | — | 0/8 (0%) | 7/8 (87.5%) |
| Levodopa-carbidopa Intestinal Gel | — | 1/6 (16.7%) | 4/6 (66.7%) |
| Event | Oral Levodopa-carbidopa Tablets | Levodopa-carbidopa Intestinal Gel |
|---|---|---|
| DelusionPsychiatric disorders | 0/8 | 1/6 |
| Hallucination, auditoryPsychiatric disorders | 0/8 | 1/6 |
| Somatic hallucinationPsychiatric disorders | 0/8 | 1/6 |
| Event | Oral Levodopa-carbidopa Tablets | Levodopa-carbidopa Intestinal Gel |
|---|---|---|
| ConstipationGastrointestinal disorders | 3/8 | 0/6 |
| InsomniaPsychiatric disorders | 3/8 | 0/6 |
| FallInjury, poisoning and procedural complications | 1/8 | 2/6 |
| DyskinesiaNervous system disorders | 0/8 | 2/6 |
| NauseaGastrointestinal disorders | 2/8 | 1/6 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 1/6 |
| StomatitisGastrointestinal disorders | 0/8 | 1/6 |
| VomitingGastrointestinal disorders | 0/8 | 1/6 |
| Intentional medical device removal by patientGeneral disorders | 0/8 | 1/6 |
| MalaiseGeneral disorders | 0/8 | 1/6 |
full safety sample
| Age, Continuous(years) | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Mean | 65.4 ± 6.19 |
| Age, Customized(participants) | Levodopa-carbidopa Intestinal Gel |
|---|---|
| < 65 years | 4 |
| >/= 65 years | 4 |
| Sex: Female, Male(Participants) | Levodopa-carbidopa Intestinal Gel |
|---|---|
| Female | 2 |
| Male | 6 |
No study locations are listed for this record.
The record gives a start of Oct 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AbbVie (prior sponsor, Abbott) →